secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENEREX PHARMA, INC. (RGPX)
CIK:        0001357878
Form:       8-K
Filed at:   2025-09-03T23:59:59+00:00
Accession:  0001472375-25-000103
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Regenerex Pharma enters exclusive collagen supply deal with Holista; minimum purchases ramp to $9M/yr
--------------------------------------------------------------------------------

- Exclusive worldwide rights to Holista's ovine collagen for wound care; initial focus on U.S. market.
- Minimum purchase commitments: $50k in 2025, $3M in 2026, $6M in 2027, $9M annually from 2028.
- Regenerex to fund clinical studies and FDA regulatory approvals for advanced wound care products.
- Joint collaboration on nano-collagen applications with shared IP ownership.
- Agreement runs for life of patents; can be terminated on 90 days' notice or for breach/insolvency.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1357878/000147237525000103/0001472375-25-000103-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1357878/000147237525000103/ixform8k.htm
  HTML page:      https://secwatch.observer/filing/0001472375-25-000103

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer